source
- Biopharma must incentivize scientists to make early go-no-go decisionsThe article argues that simply urging scientists to think like entrepreneurs is not enough; biopharma firms need to align rewards with that mindset. Because only about one in ten drug candidates t…
- Biopharma needs to reward scientists' judgmentIt’s not enough for organizations to want scientists to think like entrepreneurs. They have to incentivize and reward for that behavior.BioSpace · 21d ago↗ source
- AstraZeneca invests $2 billion in Summit Therapeutics to fund Phase 3 trials of ivonescimabAstraZeneca has agreed to a $2 billion all‑stock investment in Summit Therapeutics. The deal involves the purchase of preferred shares that can be converted into common stock, but it does not inclu…